speb/financial-data huggingface dataset:
LAB.V cash_flow (quarterly, 2025-09-30) — Unrealized Gain Loss On Investment Securities: -7653319.00
LAB.V balance_sheet (annual, 2025-09-30) — Working Capital: 16688951.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 16688951.00
LAB.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 570909.00
LAB.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 77138.00
LAB.V income_statement (quarterly, 2025-12-31) — Basic Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-12-31) — Basic EPS: 0.00
LAB.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 16766742.00
LAB.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -216706.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 15914982.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 15929402.00
LAB.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -231126.00
LAB.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -620634.00
LAB.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 91183.00
LAB.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -317358.00
LAB.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: 85429.00
LAB.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -140746.00
LAB.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: -851760.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 23361606.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 16364824.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 285255.00
LAB.V income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.00
LAB.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — EBIT: -570909.00
LAB.V income_statement (quarterly, 2025-12-31) — EBITDA: -570909.00
LAB.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 15914982.00
LAB.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -837340.00
LAB.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 529144.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 23361606.00
LAB.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -231126.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -490370.00
LAB.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -490370.00
LAB.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -490370.00
LAB.V cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -14420.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 7282037.00
LAB.V cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -216706.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 23361606.00
LAB.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -570909.00
LAB.V income_statement (quarterly, 2025-12-31) — Normalized Income: -490370.00
LAB.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -620634.00
LAB.V income_statement (quarterly, 2025-12-31) — Operating Income: -570909.00
LAB.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 4860859.00
LAB.V income_statement (quarterly, 2025-12-31) — Other Gand A: 518662.00
LAB.V income_statement (quarterly, 2025-12-31) — Other Income Expense: 80539.00
LAB.V income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 80539.00
LAB.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 41765.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 14420.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 285255.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 358284.00
LAB.V income_statement (quarterly, 2025-12-31) — Pretax Income: -490370.00
LAB.V cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -14420.00
LAB.V cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -216706.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Receivables: 77138.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -42971530.00
LAB.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 10482.00
LAB.V cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 0.00
LAB.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 529144.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 170009979.00
LAB.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 10482.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 23361606.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 23361606.00
LAB.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 23646861.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 23361606.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 23361606.00
LAB.V income_statement (quarterly, 2025-12-31) — Total Expenses: 570909.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 285255.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 7282037.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V cash_flow (quarterly, 2025-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
LAB.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 16079569.00
LAB.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 1278236.00
LAB.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 171290.00
LAB.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2026-03-31) — Basic EPS: -0.01
LAB.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 15914982.00
LAB.V cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -228282.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 13741213.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 14867531.00
LAB.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -1228282.00
LAB.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -945487.00
LAB.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 56404.00
LAB.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 298478.00
LAB.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: -94152.00
LAB.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 260730.00
LAB.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: -2173769.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 22270320.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 15098627.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 352083.00
LAB.V income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.01
LAB.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -1100570.00
LAB.V income_statement (quarterly, 2026-03-31) — EBIT: -1278236.00
LAB.V income_statement (quarterly, 2026-03-31) — EBITDA: -1278236.00
LAB.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 13741213.00
LAB.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -1173769.00
LAB.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: 111898.00
LAB.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 1178513.00
LAB.V income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 0.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: 22270320.00
LAB.V cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -1228282.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Minority Interest: 371967.00
LAB.V income_statement (quarterly, 2026-03-31) — Minority Interests: 3033.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income: -1100570.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -1100570.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -1103603.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -1100570.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -1100570.00
LAB.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -1103603.00
LAB.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -1103603.00
LAB.V cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -1000000.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Net PPE: 7895743.00
LAB.V cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -228282.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 22270320.00
LAB.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -1390134.00
LAB.V income_statement (quarterly, 2026-03-31) — Normalized Income: -1212468.00
LAB.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -945487.00
LAB.V income_statement (quarterly, 2026-03-31) — Operating Income: -1278236.00
LAB.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 4870143.00
LAB.V income_statement (quarterly, 2026-03-31) — Other Gand A: 1169229.00
LAB.V income_statement (quarterly, 2026-03-31) — Other Income Expense: 174633.00
LAB.V income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 62735.00
LAB.V income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 99723.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 1126318.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 352083.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 59806.00
LAB.V income_statement (quarterly, 2026-03-31) — Pretax Income: -1103603.00
LAB.V cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -1000000.00
LAB.V cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -228282.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Receivables: 171290.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -44072100.00
LAB.V income_statement (quarterly, 2026-03-31) — Salaries And Wages: 9284.00
LAB.V cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 0.00
LAB.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 1178513.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 170009979.00
LAB.V income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
LAB.V cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 9284.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 22270320.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 22270320.00
LAB.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 22994370.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 22270320.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 22642287.00
LAB.V income_statement (quarterly, 2026-03-31) — Total Expenses: 1278236.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 352083.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 7895743.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: 111898.00
LAB.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 111898.00
LAB.V cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: -111898.00
LAB.V balance_sheet (quarterly, 2026-03-31) — Working Capital: 14746544.00
LABS.TO cash_flow (annual, 2021-12-31) — Capital Expenditure Reported: -783000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Cash Equivalents: 226000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Cash Financial: 33884000.00
LABS.TO cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: 1093000.00
LABS.TO cash_flow (annual, 2021-12-31) — Changes In Account Receivables: 5932000.00
LABS.TO cash_flow (annual, 2021-12-31) — Common Stock Issuance: 30917000.00
LABS.TO cash_flow (annual, 2021-12-31) — Deferred Income Tax: 113000.00
LABS.TO cash_flow (annual, 2021-12-31) — Deferred Tax: 113000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Derivative Product Liabilities: 2000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Dueto Related Parties Current: 0.00
LABS.TO balance_sheet (annual, 2021-12-31) — Dueto Related Parties Non Current: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: -4509000.00
LABS.TO cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of Business: 0.00
LABS.TO income_statement (annual, 2021-12-31) — Gain On Sale Of Business: 0.00
LABS.TO balance_sheet (annual, 2021-12-31) — Investmentin Financial Assets: 0.00
LABS.TO balance_sheet (annual, 2021-12-31) — Investments And Advances: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 30917000.00
LABS.TO income_statement (annual, 2021-12-31) — Minority Interests: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 30917000.00
LABS.TO cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: 0.00
LABS.TO balance_sheet (annual, 2021-12-31) — Non Current Accounts Receivable: 123000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Non Current Deferred Liabilities: 233000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Non Current Deferred Revenue: 233000.00
LABS.TO cash_flow (annual, 2021-12-31) — Proceeds From Stock Option Exercised: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Purchase Of Investment: 0.00
LABS.TO cash_flow (annual, 2021-12-31) — Sale Of Business: 0.00
LABS.TO income_statement (annual, 2021-12-31) — Tax Provision: 113000.00
LABS.TO balance_sheet (annual, 2021-12-31) — Tradeand Other Payables Non Current: 0.00
LABS.TO income_statement (annual, 2022-12-31) — +Operating Expense: 26870000.00
LABS.TO income_statement (annual, 2022-12-31) — +Total Revenue: 22117000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Accounts Payable: 3539000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 12345000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -25043000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -6210000.00
LABS.TO cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 5000.00
LABS.TO cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 5000.00
LABS.TO cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 1369000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 829000.00
LABS.TO income_statement (annual, 2022-12-31) — Basic Average Shares: 276861109.00
LABS.TO income_statement (annual, 2022-12-31) — Basic EPS: -0.11
LABS.TO cash_flow (annual, 2022-12-31) — Beginning Cash Position: 34110000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 21055000.00
LABS.TO cash_flow (annual, 2022-12-31) — Capital Expenditure: -863000.00
LABS.TO cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -863000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 109000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Capital Stock: 191256000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 24145000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 24145000.00
LABS.TO cash_flow (annual, 2022-12-31) — Cash Dividends Paid: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Cash Equivalents: 229000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Cash Financial: 23916000.00
LABS.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 796000.00
LABS.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: 5158000.00
LABS.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -16069000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Inventory: -103000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 1754000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -515000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Payable: 1491000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 1491000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Receivables: 3612000.00
LABS.TO cash_flow (annual, 2022-12-31) — Change In Working Capital: 6239000.00
LABS.TO cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 3618000.00
LABS.TO cash_flow (annual, 2022-12-31) — Changes In Cash: -10115000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Common Stock: 191256000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Common Stock Equity: 56005000.00
LABS.TO cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Construction In Progress: 2596000.00
LABS.TO income_statement (annual, 2022-12-31) — Cost Of Revenue: 24031000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 1937000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Assets: 47345000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 75000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Debt: 523000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 598000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 492000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 492000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Current Liabilities: 9456000.00
LABS.TO cash_flow (annual, 2022-12-31) — Deferred Income Tax: -6000.00
LABS.TO cash_flow (annual, 2022-12-31) — Deferred Tax: -6000.00
LABS.TO cash_flow (annual, 2022-12-31) — Depreciation: 2867000.00
LABS.TO cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 2872000.00
LABS.TO income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 831000.00
LABS.TO cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 2872000.00
LABS.TO income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 831000.00
LABS.TO income_statement (annual, 2022-12-31) — Depreciation Income Statement: 831000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Diluted Average Shares: 276861109.00
LABS.TO income_statement (annual, 2022-12-31) — Diluted EPS: -0.11
LABS.TO income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — EBIT: -29958000.00
LABS.TO income_statement (annual, 2022-12-31) — EBITDA: -27086000.00
LABS.TO cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 150000.00
LABS.TO cash_flow (annual, 2022-12-31) — End Cash Position: 24145000.00
LABS.TO income_statement (annual, 2022-12-31) — Excise Taxes: 2866000.00
LABS.TO cash_flow (annual, 2022-12-31) — Financing Cash Flow: 796000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Finished Goods: 5550000.00
LABS.TO cash_flow (annual, 2022-12-31) — Free Cash Flow: -16932000.00
LABS.TO cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -2000.00
LABS.TO cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: 906000.00
LABS.TO cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 7000.00
LABS.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Business: -906000.00
LABS.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: -7000.00
LABS.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -740000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 28398000.00
LABS.TO income_statement (annual, 2022-12-31) — General And Administrative Expense: 22142000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 39000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 18555000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Gross PPE: 43154000.00
LABS.TO income_statement (annual, 2022-12-31) — Gross Profit: -1914000.00
LABS.TO income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Insurance And Claims: 1361000.00
LABS.TO income_statement (annual, 2022-12-31) — Interest Expense: 31000.00
LABS.TO income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 31000.00
LABS.TO income_statement (annual, 2022-12-31) — Interest Income: 479000.00
LABS.TO income_statement (annual, 2022-12-31) — Interest Income Non Operating: 479000.00
LABS.TO cash_flow (annual, 2022-12-31) — Interest Paid Cff: -26000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Inventory: 7776000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Invested Capital: 56528000.00
LABS.TO cash_flow (annual, 2022-12-31) — Investing Cash Flow: 5158000.00
LABS.TO cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
LABS.TO cash_flow (annual, 2022-12-31) — Issuance Of Debt: 1341000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Land And Improvements: 1640000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Leases: 209000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 34000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 34000.00
LABS.TO cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 1341000.00
LABS.TO cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -130000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 16749000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 6014000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -29983000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -29983000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Interest Income: 448000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 393000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -130000.00
LABS.TO income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 448000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 429000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 7000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Net PPE: 18111000.00
LABS.TO cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 0.00
LABS.TO cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 523000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 55966000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Normalized EBITDA: -25433000.00
LABS.TO income_statement (annual, 2022-12-31) — Normalized Income: -28330330.72
LABS.TO cash_flow (annual, 2022-12-31) — Operating Cash Flow: -16069000.00
LABS.TO cash_flow (annual, 2022-12-31) — Operating Gains Losses: 911000.00
LABS.TO income_statement (annual, 2022-12-31) — Operating Income: -28784000.00
LABS.TO income_statement (annual, 2022-12-31) — Operating Revenue: 24983000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 282164905.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Current Assets: 146000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 523000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 829000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: 28398000.00
LABS.TO income_statement (annual, 2022-12-31) — Other Gand A: 6696000.00
LABS.TO income_statement (annual, 2022-12-31) — Other Income Expense: -1653000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 39000.00
LABS.TO cash_flow (annual, 2022-12-31) — Other Non Cash Items: -483000.00
LABS.TO income_statement (annual, 2022-12-31) — Other Operating Expenses: 146000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Payable: 324000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Properties: 905000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Other Receivables: 501000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Payables: 3863000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 5800000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 1737000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Prepaid Assets: 1444000.00
LABS.TO income_statement (annual, 2022-12-31) — Pretax Income: -29989000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Properties: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Provision For Doubtful Accounts: 134000.00
LABS.TO cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 134000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Raw Materials: 2226000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Receivables: 13005000.00
LABS.TO income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 21990000.00
LABS.TO income_statement (annual, 2022-12-31) — Reconciled Depreciation: 2872000.00
LABS.TO income_statement (annual, 2022-12-31) — Rent And Landing Fees: 242000.00
LABS.TO income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 586000.00
LABS.TO cash_flow (annual, 2022-12-31) — Repayment Of Debt: -948000.00
LABS.TO income_statement (annual, 2022-12-31) — Research And Development: 1002000.00
LABS.TO income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Retained Earnings: -163649000.00
LABS.TO income_statement (annual, 2022-12-31) — Salaries And Wages: 13843000.00
LABS.TO cash_flow (annual, 2022-12-31) — Sale Of Business: 6014000.00
LABS.TO cash_flow (annual, 2022-12-31) — Sale Of PPE: 0.00
LABS.TO income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 2615000.00
LABS.TO income_statement (annual, 2022-12-31) — Selling General And Administration: 24757000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Share Issued: 282164905.00
LABS.TO cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 1341000.00
LABS.TO cash_flow (annual, 2022-12-31) — Short Term Debt Payments: -818000.00
LABS.TO income_statement (annual, 2022-12-31) — Special Income Charges: -913000.00
LABS.TO cash_flow (annual, 2022-12-31) — Stock Based Compensation: 2872000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Stockholders Equity: 56005000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Tangible Book Value: 55966000.00
LABS.TO income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -330.72
LABS.TO income_statement (annual, 2022-12-31) — Tax Provision: -6000.00
LABS.TO income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
LABS.TO balance_sheet (annual, 2022-12-31) — Taxes Receivable: 159000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Assets: 65495000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Capitalization: 56005000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Debt: 632000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 56005000.00
LABS.TO income_statement (annual, 2022-12-31) — Total Expenses: 50901000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 9490000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 18150000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 34000.00
LABS.TO income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -29533000.00
LABS.TO income_statement (annual, 2022-12-31) — Total Unusual Items: -1653000.00
LABS.TO income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -1653000.00
LABS.TO balance_sheet (annual, 2022-12-31) — Working Capital: 37889000.00
LABS.TO income_statement (annual, 2022-12-31) — Write Off: 0.00
LABS.TO income_statement (annual, 2023-12-31) — +Operating Expense: 23602000.00
LABS.TO income_statement (annual, 2023-12-31) — +Total Revenue: 33062000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Accounts Payable: 2130000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Accounts Receivable: 5515000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -26982000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -208000.00
LABS.TO cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 112000.00
LABS.TO cash_flow (annual, 2023-12-31) — Amortization Of Intangibles: 112000.00
LABS.TO cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 1749000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Assets Held For Sale Current: 1793000.00
LABS.TO income_statement (annual, 2023-12-31) — Basic Average Shares: 363323952.00
LABS.TO income_statement (annual, 2023-12-31) — Basic EPS: -0.04
LABS.TO cash_flow (annual, 2023-12-31) — Beginning Cash Position: 24145000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 28179000.00
LABS.TO cash_flow (annual, 2023-12-31) — Capital Expenditure: -471000.00
LABS.TO cash_flow (annual, 2023-12-31) — Capital Expenditure Reported: -471000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 190000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Capital Stock: 200244000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 17981000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 17981000.00
LABS.TO cash_flow (annual, 2023-12-31) — Cash Dividends Paid: 0.00
LABS.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -368000.00
LABS.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 6872000.00
LABS.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -12339000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Inventory: 3267000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -1221000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 150000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Other Working Capital: 150000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Payable: -5166000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -5166000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Receivables: 6420000.00
LABS.TO cash_flow (annual, 2023-12-31) — Change In Working Capital: 3450000.00
LABS.TO cash_flow (annual, 2023-12-31) — Changes In Account Receivables: 6291000.00
LABS.TO cash_flow (annual, 2023-12-31) — Changes In Cash: -5835000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Common Stock: 200244000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 53005000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Construction In Progress: 2502000.00
LABS.TO income_statement (annual, 2023-12-31) — Cost Of Revenue: 27207000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 2385000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Assets: 36633000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 121000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Debt: 2105000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 2226000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 391000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 391000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Current Liabilities: 10863000.00
LABS.TO cash_flow (annual, 2023-12-31) — Depreciation: 2404000.00
LABS.TO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 2516000.00
LABS.TO income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 453000.00
LABS.TO cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 2516000.00
LABS.TO income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 453000.00
LABS.TO income_statement (annual, 2023-12-31) — Depreciation Income Statement: 453000.00
LABS.TO income_statement (annual, 2023-12-31) — Diluted Average Shares: 363323952.00
LABS.TO income_statement (annual, 2023-12-31) — Diluted EPS: -0.04
LABS.TO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — EBIT: -12994000.00
LABS.TO income_statement (annual, 2023-12-31) — EBITDA: -10478000.00
LABS.TO cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -329000.00
LABS.TO cash_flow (annual, 2023-12-31) — End Cash Position: 17981000.00
LABS.TO income_statement (annual, 2023-12-31) — Excise Taxes: 3757000.00
LABS.TO cash_flow (annual, 2023-12-31) — Financing Cash Flow: -368000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Finished Goods: 6418000.00
LABS.TO cash_flow (annual, 2023-12-31) — Free Cash Flow: -12810000.00
LABS.TO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 251000.00
LABS.TO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: -173000.00
LABS.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Business: -251000.00
LABS.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: 174000.00
LABS.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -456000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 29493000.00
LABS.TO income_statement (annual, 2023-12-31) — General And Administrative Expense: 21635000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 1032000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 5723000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Gross PPE: 52254000.00
LABS.TO income_statement (annual, 2023-12-31) — Gross Profit: 5855000.00
LABS.TO income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 183000.00
LABS.TO income_statement (annual, 2023-12-31) — Insurance And Claims: 959000.00
LABS.TO income_statement (annual, 2023-12-31) — Interest Expense: 365000.00
LABS.TO income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 365000.00
LABS.TO income_statement (annual, 2023-12-31) — Interest Income: 840000.00
LABS.TO income_statement (annual, 2023-12-31) — Interest Income Non Operating: 840000.00
LABS.TO cash_flow (annual, 2023-12-31) — Interest Paid Cff: -264000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Inventory: 9899000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Invested Capital: 55110000.00
LABS.TO cash_flow (annual, 2023-12-31) — Investing Cash Flow: 6872000.00
LABS.TO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 1066000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Land And Improvements: 2930000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Leases: 209000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 69000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 69000.00
LABS.TO cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 1066000.00
LABS.TO cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -248000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 17529000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 5262000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: 191000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -13083000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -13083000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Interest Income: 475000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -944000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 818000.00
LABS.TO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 475000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 840000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 1903000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Net PPE: 25272000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: 178000.00
LABS.TO cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: -1762000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 51973000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 1000000.00
LABS.TO income_statement (annual, 2023-12-31) — Normalized EBITDA: -14391000.00
LABS.TO income_statement (annual, 2023-12-31) — Normalized Income: -16915156.52
LABS.TO cash_flow (annual, 2023-12-31) — Operating Cash Flow: -12339000.00
LABS.TO cash_flow (annual, 2023-12-31) — Operating Gains Losses: 269000.00
LABS.TO income_statement (annual, 2023-12-31) — Operating Income: -17747000.00
LABS.TO income_statement (annual, 2023-12-31) — Operating Revenue: 36819000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 401397439.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Current Assets: 194000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 2105000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 829000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 29493000.00
LABS.TO income_statement (annual, 2023-12-31) — Other Gand A: 6084000.00
LABS.TO income_statement (annual, 2023-12-31) — Other Income Expense: 3913000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 1032000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Inventories: 12000.00
LABS.TO cash_flow (annual, 2023-12-31) — Other Non Cash Items: -7345000.00
LABS.TO income_statement (annual, 2023-12-31) — Other Operating Expenses: 66000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Payable: 382000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Properties: 905000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Other Receivables: 79000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Payables: 2512000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 4897000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 2520000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Prepaid Assets: 900000.00
LABS.TO income_statement (annual, 2023-12-31) — Pretax Income: -13359000.00
LABS.TO cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 0.00
LABS.TO balance_sheet (annual, 2023-12-31) — Properties: 0.00
LABS.TO income_statement (annual, 2023-12-31) — Provision For Doubtful Accounts: -1922000.00
LABS.TO cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: -1922000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Raw Materials: 3469000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Receivables: 5866000.00
LABS.TO income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 25144000.00
LABS.TO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 2516000.00
LABS.TO income_statement (annual, 2023-12-31) — Rent And Landing Fees: 582000.00
LABS.TO income_statement (annual, 2023-12-31) — Rent Expense Supplemental: 1300000.00
LABS.TO cash_flow (annual, 2023-12-31) — Repayment Of Debt: -2010000.00
LABS.TO income_statement (annual, 2023-12-31) — Research And Development: 209000.00
LABS.TO income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: -4669000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: -176732000.00
LABS.TO income_statement (annual, 2023-12-31) — Salaries And Wages: 14010000.00
LABS.TO cash_flow (annual, 2023-12-31) — Sale Of Business: 5262000.00
LABS.TO cash_flow (annual, 2023-12-31) — Sale Of PPE: 178000.00
LABS.TO income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 3161000.00
LABS.TO income_statement (annual, 2023-12-31) — Selling General And Administration: 24796000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Share Issued: 401397439.00
LABS.TO cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 1066000.00
LABS.TO cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -1762000.00
LABS.TO income_statement (annual, 2023-12-31) — Special Income Charges: 4369000.00
LABS.TO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 2027000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 53005000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 51973000.00
LABS.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 80843.48
LABS.TO income_statement (annual, 2023-12-31) — Tax Provision: -276000.00
LABS.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.02
LABS.TO balance_sheet (annual, 2023-12-31) — Taxes Receivable: 272000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Assets: 63937000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 53005000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Debt: 2295000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 53005000.00
LABS.TO income_statement (annual, 2023-12-31) — Total Expenses: 50809000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 10932000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 27304000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 69000.00
LABS.TO income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -18252000.00
LABS.TO income_statement (annual, 2023-12-31) — Total Unusual Items: 3913000.00
LABS.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 3913000.00
LABS.TO balance_sheet (annual, 2023-12-31) — Working Capital: 25770000.00
LABS.TO income_statement (annual, 2023-12-31) — Write Off: 40000.00
LABS.TO income_statement (quarterly, 2024-09-30) — Basic EPS: -0.01
LABS.TO cash_flow (quarterly, 2024-09-30) — Changes In Account Receivables: -473000.00
LABS.TO income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.01
LABS.TO cash_flow (quarterly, 2024-09-30) — Issuance Of Debt: 50000.00
LABS.TO cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 50000.00
LABS.TO cash_flow (quarterly, 2024-09-30) — Net Business Purchase And Sale: 0.00
LABS.TO income_statement (quarterly, 2024-09-30) — Restructuring And Mergern Acquisition: 0.00
LABS.TO cash_flow (quarterly, 2024-09-30) — Sale Of Business: 0.00
LABS.TO income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
LABS.TO income_statement (quarterly, 2024-09-30) — Tax Provision: 0.00
LABS.TO income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
LABS.TO income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
LABS.TO income_statement (annual, 2024-12-31) — +Operating Expense: 23696000.00
LABS.TO income_statement (annual, 2024-12-31) — +Total Revenue: 41961000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 4237000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 6878000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -23323000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -78000.00
LABS.TO balance_sheet (quarterly, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -78000.00
LABS.TO cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 178000.00
LABS.TO cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 178000.00
LABS.TO cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 466000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Assets Held For Sale Current: 4348000.00
LABS.TO balance_sheet (quarterly, 2024-12-31) — Assets Held For Sale Current: 4348000.00
LABS.TO income_statement (annual, 2024-12-31) — Basic Average Shares: 407993353.00
LABS.TO income_statement (annual, 2024-12-31) — Basic EPS: -0.03
LABS.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 17981000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 25263000.00
LABS.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -154000.00
LABS.TO cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -44000.00
LABS.TO cash_flow (annual, 2024-12-31) — Capital Expenditure Reported: -154000.00
LABS.TO cash_flow (quarterly, 2024-12-31) — Capital Expenditure Reported: -44000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 130000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 201210000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 11690000.00
LABS.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 11690000.00
LABS.TO cash_flow (annual, 2024-12-31) — Cash Dividends Paid: 0.00
LABS.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -1847000.00